Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Asset icon - trade crypto, stocks, and gold on Pluang

Buy & Sell Abeona Therapeutics Inc (ABEO) – Abeona Therapeutics Inc Price Today

24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Abeona Therapeutics (ABEO) trades at $5.68, down 3.07% on the day, amid a bullish technical signal and strong analyst consensus. The company shows exceptional profitability metrics with a net income margin of 1,223.08% and ROE of 70.05%, though revenue remains modest at $6M. Recent news highlights momentum from the commercial launch of ZEVASKYN, its FDA-approved gene therapy for RDEB, with the first patient treatment completed in December 2025.
The outlook is positive, driven by ZEVASKYN's commercial potential targeting a multi-billion dollar opportunity. Investment opportunities include strong earnings beats and a favorable valuation with a P/E of 5.63. Key risks involve execution of the commercial launch, reliance on a single product, and the company's modest revenue base relative to its market valuation.
Read full analysis

Key Stats

  • Market Cap
    $324.80M
  • Sector
    Health
  • 3M Drawdown
    -21.67%
  • Enterprise Value
    $179.70M
  • Dividend Yield
    -
  • Trading Activity
    100% Buy | 0% Sell
  • Typical Hold Time
    4 days
$5.47
52W Low: $4.17
11 Nov 2025
52W High: $7.23
22 Aug 2025

Abeona Therapeutics Inc (ABEO) is currently valued at a market capitalization of $324.80M, with an enterprise value of $179.70M. Over the past 52 weeks, Abeona Therapeutics Inc has traded between a low of $4.17 and a high of $7.23, highlighting its annual price range. Over the past three months, Abeona Therapeutics Inc has recorded a drawdown of -21.67%, reflecting recent price volatility. On average, investors hold Abeona Therapeutics Inc for approximately 4 days, indicating typical investor behavior on the platform.

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.


Technical Indicators
|
|
|
Overall Summary
Bearish (8)Neutral (4)Bullish (15)

People also bought


US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions

Key Stats

  • Market Cap
    $324.80M
  • Sector
    Health
  • 3M Drawdown
    -21.67%
  • Enterprise Value
    $179.70M
  • Dividend Yield
    -
  • Trading Activity
    100% Buy | 0% Sell
  • Typical Hold Time
    4 days
$5.47
52W Low: $4.17
11 Nov 2025
52W High: $7.23
22 Aug 2025

Abeona Therapeutics Inc (ABEO) is currently valued at a market capitalization of $324.80M, with an enterprise value of $179.70M. Over the past 52 weeks, Abeona Therapeutics Inc has traded between a low of $4.17 and a high of $7.23, highlighting its annual price range. Over the past three months, Abeona Therapeutics Inc has recorded a drawdown of -21.67%, reflecting recent price volatility. On average, investors hold Abeona Therapeutics Inc for approximately 4 days, indicating typical investor behavior on the platform.

Let’s invest in this asset by signing up or download!